IL280721A - A method for treating relapse of follicular lymphoma - Google Patents

A method for treating relapse of follicular lymphoma

Info

Publication number
IL280721A
IL280721A IL280721A IL28072121A IL280721A IL 280721 A IL280721 A IL 280721A IL 280721 A IL280721 A IL 280721A IL 28072121 A IL28072121 A IL 28072121A IL 280721 A IL280721 A IL 280721A
Authority
IL
Israel
Prior art keywords
treatment
follicular lymphoma
relapsed follicular
relapsed
lymphoma
Prior art date
Application number
IL280721A
Other languages
English (en)
Hebrew (he)
Original Assignee
Mei Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mei Pharma Inc filed Critical Mei Pharma Inc
Publication of IL280721A publication Critical patent/IL280721A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL280721A 2018-08-14 2021-02-08 A method for treating relapse of follicular lymphoma IL280721A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862718926P 2018-08-14 2018-08-14
US201962836507P 2019-04-19 2019-04-19
PCT/US2019/046408 WO2020036997A1 (en) 2018-08-14 2019-08-13 Treatment of relapsed follicular lymphoma

Publications (1)

Publication Number Publication Date
IL280721A true IL280721A (en) 2021-03-25

Family

ID=69525835

Family Applications (1)

Application Number Title Priority Date Filing Date
IL280721A IL280721A (en) 2018-08-14 2021-02-08 A method for treating relapse of follicular lymphoma

Country Status (14)

Country Link
US (1) US20210196725A1 (enExample)
EP (1) EP3836936A4 (enExample)
JP (1) JP2021534116A (enExample)
KR (1) KR20210043637A (enExample)
CN (1) CN112839659A (enExample)
AU (1) AU2019321526A1 (enExample)
BR (1) BR112021002734A2 (enExample)
CA (1) CA3109377A1 (enExample)
IL (1) IL280721A (enExample)
MA (1) MA53237A (enExample)
MX (1) MX2021001765A (enExample)
SG (1) SG11202101417XA (enExample)
TW (1) TW202021593A (enExample)
WO (1) WO2020036997A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107501241B (zh) 2011-03-28 2020-10-13 梅制药公司 化合物、含有其的药物组合物以及它们在治疗增生性疾病中的用途
EP3630118A4 (en) 2017-05-23 2021-03-31 MEI Pharma, Inc. COMBINATION THERAPY
MX2020001727A (es) 2017-08-14 2020-03-20 Mei Pharma Inc Terapia de combinacion.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2919869B1 (fr) * 2007-08-09 2009-09-25 Sanofi Aventis Sa Nouveaux derives de n, n'-2,4-dianilinopyrimidines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
CN107501241B (zh) * 2011-03-28 2020-10-13 梅制药公司 化合物、含有其的药物组合物以及它们在治疗增生性疾病中的用途
UA116544C2 (uk) * 2012-08-09 2018-04-10 Селджин Корпорейшн Спосіб лікування раку з використанням 3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону
MA38462A1 (fr) * 2013-04-08 2017-10-31 Bayer Pharma AG Utilisation de 2,3-dihydroimidazo[1,2-c]quinazolines substituées pour le traitement de lymphomes
CA2979671C (en) * 2014-09-23 2020-03-10 Genentech, Inc. Methods of using anti-cd79b immunoconjugates
CN109982687A (zh) * 2016-09-19 2019-07-05 梅制药公司 联合疗法
MX2020001727A (es) * 2017-08-14 2020-03-20 Mei Pharma Inc Terapia de combinacion.

Also Published As

Publication number Publication date
WO2020036997A1 (en) 2020-02-20
US20210196725A1 (en) 2021-07-01
CA3109377A1 (en) 2020-02-20
MX2021001765A (es) 2021-04-19
BR112021002734A2 (pt) 2021-07-20
TW202021593A (zh) 2020-06-16
EP3836936A4 (en) 2022-05-18
CN112839659A (zh) 2021-05-25
SG11202101417XA (en) 2021-03-30
KR20210043637A (ko) 2021-04-21
JP2021534116A (ja) 2021-12-09
AU2019321526A1 (en) 2021-03-25
EP3836936A1 (en) 2021-06-23
MA53237A (fr) 2021-06-23

Similar Documents

Publication Publication Date Title
ZA202006627B (en) Methods and compositions for treating cancer
IL276808A (en) Preparations and methods for the treatment of cancer
MX2019001471A (es) Anticuerpos anti-siglec-7 para el tratamiento del cancer.
ZA201900960B (en) Methods and compositions for the treatment of cancer
GB201804514D0 (en) Treatment of pyroptosis
MX2022015753A (es) Metodos y composiciones para tratamiento de epidermolisis ampollosa.
SG11202012435UA (en) Compositions and methods for treating cancer
SG11202011117VA (en) Treatment of cancer
ZA201808232B (en) Compositions and methods for the treatment of cancer
GB201804515D0 (en) Treatment of necroptosis
SG11202101417XA (en) Treatment of relapsed follicular lymphoma
IL282948B2 (en) Cancer treatment preparations and methods
IL283885A (en) cxcr7 inhibitors for cancer therapy
IL273909A (en) Treatment of CD20-positive B-cell lymphoma with obituzumab
IL265387A (en) Treatment of non-hodgkin lymphoma using lilotomab and 177lu-lilotomab satetraxetan
GB201820098D0 (en) Methods of cancer treatment
SG11202000724XA (en) Methods and compositions for the treatment of cancer
IL280262A (en) Compositions and methods for treating cancer
HK40053748A (en) Treatment of relapsed follicular lymphoma
GB201918815D0 (en) Treatment of cancer
GB201820975D0 (en) Methods of cancer treatment
SG11202105309YA (en) Methods of treating follicular lymphoma
HK40061099A (en) Methods of treating follicular lymphoma
ZA202101900B (en) Cosmetic treatment process
GB201915003D0 (en) Treatment of hepatotoxicity